A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Brugge-AZBRUGGE, Bruges

BE-Bruxelles-STLUC, Brussels

BE-Haine-Saint-Paul-JOLIMONT, Haine-Saint-Paul

BE-Leuven-UZLEUVEN, Leuven

DK-Aalborg-AALBORGUH, Aalborg

DK-Copenhagen-RIGSHOSPITALET, Copenhagen

DK-Herlev-HERLEV, Herlev

DK-Holstebro-HOLSTEBRO, Holstebro

DK-Odense-OUH, Odense

DK-Roskilde-ROSKILDE, Roskilde

FI-Helsinki-HUS, Helsinki

FI-Jyvaskyla-KSSHP, Jyväskylä

FI-Kuopio-KYS, Kuopio

FI-Tampere-TAYS, Tampere

FI-Turku-TYKS, Turku

NL-Alkmaar-NWZ, Alkmaar

NL-Amersfoort-MEANDERMC, Amersfoort

NL-Amsterdam-AMC, Amsterdam

NL-Amsterdam-AVL, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Arnhem-RIJNSTATE, Arnhem

NL-Breda-AMPHIA, Breda

NL-Delft-RDGG, Delft

NL-Dordrecht-ASZ, Dordrecht

NL-Enschede-MST, Enschede

NL-Gouda-GROENEHART, Gouda

NL-Groningen-UMCG, Groningen

NL-Heerlen-ATRIUMMC, Heerlen

NL-Helmond-ELKERLIEK, Helmond

NL-Nieuwegein-ANTONIUS, Nieuwegein

NL-Nijmegen-CWZ, Nijmegen

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Rotterdam-MAASSTADZIEKENHUIS, Rotterdam

NL-Sittard-Geleen-ZUYDERLAND, Sittard

NL-Sneek-ANTONIUSSNEEK, Sneek

NL-Den Haag-HAGA, The Hague

NL-Tilburg-ETZ, Tilburg

NL-Uden-BERNHOVEN, Uden

NL-Utrecht-UMCUTRECHT, Utrecht

NL-Zaandam-ZAANSMC, Zaandam

NL-Zwolle-ISALA, Zwolle

NO-Lørenskog-AKERSHUS, Lørenskog

NO-Trondheim-STOLAV, Trondheim

SE-Boras-SASBORAS, Borås

SE-Linköping-REGIONOSTERGOTLAND, Linköping

SE-Luleå-SUNDERBY, Luleå

SE-Lund-SUH, Lund

SE-Uppsala-UPPSALAUH, Uppsala